Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LSTA 
Lisata Therapeutics Inc. (LSTA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/28/2025: LSTA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $20.67
1 Year Target Price $20.67
| 1 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -43.15% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 24.52M USD | Price to earnings Ratio - | 1Y Target Price 20.67 |
Price to earnings Ratio - | 1Y Target Price 20.67 | ||
Volume (30-day avg) 3 | Beta 1.04 | 52 Weeks Range 1.87 - 4.20 | Updated Date 10/28/2025 |
52 Weeks Range 1.87 - 4.20 | Updated Date 10/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.23 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -6954.29% |
Management Effectiveness
Return on Assets (TTM) -38.76% | Return on Equity (TTM) -64.4% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 404667 | Price to Sales(TTM) 22.91 |
Enterprise Value 404667 | Price to Sales(TTM) 22.91 | ||
Enterprise Value to Revenue 0.38 | Enterprise Value to EBITDA 0.82 | Shares Outstanding 8755948 | Shares Floating 7259644 |
Shares Outstanding 8755948 | Shares Floating 7259644 | ||
Percent Insiders 19.82 | Percent Institutions 8.94 |
Upturn AI SWOT
Lisata Therapeutics Inc.
Company Overview
History and Background
Lisata Therapeutics, Inc. (LSTA), formerly Celsion Corporation, focuses on developing innovative therapies for the treatment of solid tumors. Founded to leverage Heat Shock Protein-based technology, it has evolved to focus on its investigational drug candidate, LSTA1.
Core Business Areas
- Drug Development: Development of LSTA1, a novel drug designed to target solid tumors and enhance the delivery of other anti-cancer agents.
Leadership and Structure
Lisata Therapeutics has a management team led by the CEO and supported by various departments like research and development, clinical operations, and finance. The Board of Directors provides oversight and guidance.
Top Products and Market Share
Key Offerings
- LSTA1: LSTA1 is Lisata's primary investigational drug candidate. It is designed to target solid tumors and enhance the delivery of anti-cancer agents. Since LSTA1 is in clinical development, there is currently no market share or revenue. Competitors include companies developing other tumor-targeting drug delivery systems.
Market Dynamics
Industry Overview
The oncology market is large and growing, with significant unmet needs for effective and targeted cancer therapies. Drug delivery is a major focus within this market segment.
Positioning
Lisata is positioning itself as a leader in tumor-targeted drug delivery, leveraging LSTA1's unique mechanism of action to improve the efficacy of existing cancer treatments.
Total Addressable Market (TAM)
The TAM for cancer therapies is estimated to be hundreds of billions of dollars globally. Lisata's success hinges on LSTA1's ability to capture a meaningful share of this market by enhancing existing therapies. Due to their development stage, it's difficult to put a specific value on the TAM they target.
Upturn SWOT Analysis
Strengths
- Novel drug candidate (LSTA1) with a unique mechanism of action.
- Potential to enhance the efficacy of existing cancer treatments.
- Experienced management team.
Weaknesses
- Reliance on a single drug candidate.
- Clinical development risk.
- Limited financial resources.
- No approved products yet
Opportunities
- Positive clinical trial results for LSTA1.
- Partnerships with pharmaceutical companies.
- Expansion into new indications.
- Government grants and funding opportunities
Threats
- Competition from established pharmaceutical companies.
- Regulatory hurdles.
- Failure of clinical trials.
- Economic downturn affecting investment in biotech.
Competitors and Market Share
Key Competitors
- BMRN
- ARVN
- NKTR
- ALNY
Competitive Landscape
Lisata competes in the oncology space, specifically related to drug delivery technology. Success depends on demonstrating superior efficacy and safety compared to other treatments in clinical trials and obtaining regulatory approval. It is disadvantaged compared to larger, more established pharmaceutical companies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's pre-revenue stage, with growth tied to clinical trial milestones and strategic deals.
Future Projections: Future growth depends on the successful development and commercialization of LSTA1 and other pipeline candidates. Analyst estimates vary widely based on clinical trial outcomes.
Recent Initiatives: Recent initiatives include ongoing clinical trials for LSTA1 in various solid tumor types.
Summary
Lisata Therapeutics is a development-stage biotech company focused on its lead drug candidate, LSTA1. Its potential lies in the drug's novel mechanism for tumor-targeted drug delivery. However, it faces significant clinical and financial risks inherent in drug development. Successful clinical trials and strategic partnerships are crucial for its future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Lisata Therapeutics Inc. SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided is based on available information and subject to change. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lisata Therapeutics Inc.
Exchange NASDAQ | Headquaters Basking Ridge, NJ, United States | ||
IPO Launch date 1999-03-01 | President, CEO & Director Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 26 | Website https://www.lisata.com |
Full time employees 26 | Website https://www.lisata.com | ||
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with a range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.